• 1. Excimer emission and magnetoluminescence of radical-based zinc(ii) complexes doped in host crystals?
  Shojiro Kimura,Tetsuro Kusamoto Chem. Commun., 2020,56, 11195-11198
• 2. EWOD-driven droplet microfluidic device integrated with optoelectronic tweezers as an automated platform for cellular isolation and analysis?
  Gaurav J. Shah,Eric P.-Y. Chiou,Ming C. Wu,Chang-Jin “CJ” Kim Lab Chip, 2009,9, 1732-1739
• 3. Excimer–monomer switch: a reaction-based approach for selective detection of fluoride?
  Qiao Song,Angela Bamesberger,Lingyun Yang,Haley Houtwed,Haishi Cao Analyst, 2014,139, 3588-3592
• 4. Examination of the hydrogen-bonding networks in small water clusters (n = 2–5, 13, 17) using absolutely localized molecular orbital energy decomposition analysis?
  Erika A. Cobar,Paul R. Horn,Robert G. Bergman,Martin Head-Gordon Phys. Chem. Chem. Phys., 2012,14, 15328-15339
• 5. Evolved polymerases facilitate selection of fully 2′-OMe-modified aptamers?
  Zhixia Liu,Tingjian Chen,Floyd E. Romesberg Chem. Sci., 2017,8, 8179-8182

7H-pyrrolo[2,3-d]pyrimidin-2-ylmethanol (CAS 1638760-23-2): A Comprehensive Overview

In the rapidly evolving field of pharmaceutical chemistry, 7H-pyrrolo[2,3-d]pyrimidin-2-ylmethanol (CAS 1638760-23-2) has emerged as a compound of significant interest. This heterocyclic molecule, belonging to the pyrrolopyrimidine class, has garnered attention for its potential applications in drug discovery and medicinal chemistry. Researchers are particularly drawn to its unique molecular structure, which combines a pyrrole and pyrimidine ring system with a hydroxymethyl functional group at the 2-position.

The compound 7H-pyrrolo[2,3-d]pyrimidin-2-ylmethanol represents an important scaffold in modern drug design. Its structural features make it particularly valuable as a building block for more complex molecules, especially in the development of kinase inhibitors. The presence of both nitrogen-rich heterocycles and a reactive hydroxymethyl group allows for diverse chemical modifications, making it a versatile intermediate in organic synthesis.

Recent studies have highlighted the potential of pyrrolopyrimidine derivatives in targeting various biological pathways. The 7H-pyrrolo[2,3-d]pyrimidin-2-ylmethanol core structure has shown promise in the development of compounds with potential therapeutic applications, particularly in areas such as oncology and inflammation. This aligns with current research trends focusing on small molecule drug discovery and targeted therapies.

The synthesis of 7H-pyrrolo[2,3-d]pyrimidin-2-ylmethanol typically involves multi-step organic reactions starting from commercially available pyrrolopyrimidine precursors. Modern synthetic approaches often employ green chemistry principles to improve yield and reduce environmental impact, reflecting the pharmaceutical industry's growing commitment to sustainable practices. The compound's purity and characterization are typically confirmed through advanced analytical techniques including HPLC, NMR spectroscopy, and mass spectrometry.

From a commercial perspective, CAS 1638760-23-2 has seen increasing demand from pharmaceutical researchers and contract research organizations. The compound is typically supplied as a high-purity powder with detailed certificates of analysis, meeting the stringent requirements of drug development programs. Current market trends show growing interest in such specialized pharmaceutical intermediates, particularly those with potential applications in precision medicine approaches.

In terms of physical properties, 7H-pyrrolo[2,3-d]pyrimidin-2-ylmethanol is generally characterized as a solid at room temperature with specific solubility characteristics that make it suitable for various organic reactions. Its stability profile and handling requirements are important considerations for researchers working with this compound in laboratory settings. Proper storage conditions typically involve protection from moisture and maintenance at controlled temperatures.

The intellectual property landscape surrounding pyrrolopyrimidine derivatives has become increasingly active, with numerous patents filed for related compounds and their therapeutic applications. While 7H-pyrrolo[2,3-d]pyrimidin-2-ylmethanol itself may not be patented, its derivatives are frequently the subject of patent applications, particularly in the areas of kinase inhibition and signal transduction modulation.

Quality control for CAS 1638760-23-2 follows rigorous pharmaceutical standards, with suppliers typically providing comprehensive analytical data to ensure batch-to-batch consistency. This is particularly important given the compound's potential use in preclinical research and early-stage drug development programs. The pharmaceutical industry's increasing focus on quality by design principles has further elevated the standards for such specialized intermediates.

From a regulatory perspective, 7H-pyrrolo[2,3-d]pyrimidin-2-ylmethanol is generally classified as a research chemical rather than an active pharmaceutical ingredient. However, researchers working with this compound must still adhere to appropriate laboratory safety protocols and chemical handling procedures. The compound's material safety data sheet provides essential information regarding its proper handling, storage, and disposal.

Looking to the future, the pyrrolopyrimidine scaffold represented by 7H-pyrrolo[2,3-d]pyrimidin-2-ylmethanol is likely to remain an area of active research. The ongoing exploration of targeted cancer therapies and the continued need for novel small molecule modulators of biological pathways ensure sustained interest in such chemical entities. As drug discovery approaches become more sophisticated, the demand for high-quality, well-characterized building blocks like CAS 1638760-23-2 is expected to grow correspondingly.

In conclusion, 7H-pyrrolo[2,3-d]pyrimidin-2-ylmethanol represents an important tool in modern medicinal chemistry research. Its unique structural features, combined with its versatility as a synthetic intermediate, make it valuable for pharmaceutical development. As research into kinase inhibitors and other targeted therapies continues to advance, compounds like 7H-pyrrolo[2,3-d]pyrimidin-2-ylmethanol will likely play an increasingly important role in the discovery of new therapeutic agents.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)